Skip to main content
NORTHEAST PHARMACEUTICAL GROUP CO.,LTD logo

NORTHEAST PHARMACEUTICAL GROUP CO.,LTD — Investor Relations & Filings

Ticker · 000597 ISIN · CNE0000009G0 LEI · 300300HX6JTMOEENF158 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,606 across all filing types
Latest filing 2024-07-25 Capital/Financing Update
Country CN China
Listing Shenzhen Stock Exchange 000597

About NORTHEAST PHARMACEUTICAL GROUP CO.,LTD

https://www.nepharm.com.cn

Northeast Pharmaceutical Group Co., Ltd. (NEPG) specializes in the research, development, manufacture, and distribution of active pharmaceutical ingredients (APIs) and finished dosage forms. The company operates as a large-scale integrated pharmaceutical enterprise with a diverse product portfolio encompassing vitamins, antibiotics, cardiovascular agents, and digestive system medications. NEPG is recognized as a global leader in the production of Vitamin C and Vitamin B1, alongside significant output in caffeine and fosfomycin. Its manufacturing facilities adhere to international quality standards, including Good Manufacturing Practice (GMP) certifications. The company serves a broad international market, exporting products to numerous countries while maintaining a strong domestic presence. NEPG focuses on technological innovation and industrial scaling to provide high-quality chemical raw materials and pharmaceutical preparations for global healthcare needs.

Recent filings

Filing Released Lang Actions
关于调整2022年限制性股票激励计划首次授予及预留授予回购价格的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding adjustments to the 2022 restricted stock incentive plan, specifically about the first grant and reserved grant repurchase prices. It details board and supervisory meetings, approvals, legal opinions, and the rationale and method for adjusting the repurchase price of restricted stock. The document is a formal public announcement of these changes and related corporate actions, including repurchase and cancellation of shares under the stock incentive plan. It does not contain financial statements or detailed financial performance data, nor is it a transcript, report, or presentation. It is a regulatory announcement about stock incentive plan adjustments and repurchase prices, which fits best under the category of Capital/Financing Update (CAP), as it relates to changes in equity incentives and repurchase pricing affecting capital structure.
2024-07-25 Chinese
关于子公司获得药品注册证书的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement by Dongbei Pharmaceutical Group Co., Ltd. regarding its subsidiary receiving a drug registration certificate from the National Medical Products Administration. It details the drug's registration information, approval, and potential impact on the company. The document is short (1221 characters) and serves as an official announcement of a regulatory approval event rather than a financial report or detailed management discussion. It does not contain financial statements, earnings data, or management analysis. It is not a report itself but an announcement of a regulatory event. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2024-07-08 Chinese
诉讼进展公告
Legal Proceedings Report Classification · 95% confidence The document is a litigation progress announcement from Dongbei Pharmaceutical Group Co., Ltd. It details the status of a specific lawsuit, including court decisions and potential financial impacts. The text does not contain financial statements or comprehensive financial data, but rather legal updates and case details. It is not an annual report, earnings release, or any financial report. It is clearly a legal proceedings update, fitting the category of Legal Proceedings Report (LTR). The document length is short and focused on litigation, not a report publication or certification. Therefore, the appropriate classification is LTR with high confidence.
2024-06-25 Chinese
第九届董事会第二十七次会议决议公告
Board/Management Information Classification · 100% confidence The document is a formal announcement of a board meeting resolution by Northeast Pharmaceutical Group Co., Ltd. It details the convening of the 27th meeting of the 9th Board of Directors, the attendance, the legality of the meeting, and the approval of the appointment of a new board secretary. It includes voting results and references a related announcement for more details. The content focuses on board/management changes and does not contain financial data or report content. The document length is short (639 characters), and it is clearly a board/management information announcement rather than a full report or financial statement.
2024-06-19 Chinese
关于聘任阎小佳先生为公司董事会秘书的公告
Board/Management Information Classification · 100% confidence The document is an announcement regarding the appointment of Mr. Yan Xiaojia as the company's board secretary. It includes details about the board meeting date, the approval of the appointment, the qualifications and background of the appointee, and compliance with relevant laws and regulations. There is no financial data, earnings information, or report publication mentioned. The content clearly relates to a change in senior management or board-related personnel. Therefore, the document fits the category of Board/Management Information (MANG). The document length is short and focused solely on this appointment, confirming it is not a full report or other type of filing.
2024-06-19 Chinese
关于公司原料药维生素C收到欧洲药品质量管理局签发CEP证书的公告
Regulatory Filings Classification · 95% confidence The document is an announcement from Dongbei Pharmaceutical Group Co., Ltd. regarding the receipt of a CEP certificate issued by the European Directorate for the Quality of Medicines (EDQM) for their Vitamin C raw material. It includes details about the certificate, the product, and the impact on the company. The document is short (739 characters) and serves as a formal announcement of a regulatory or certification event rather than a financial report or detailed management discussion. It does not contain financial data, management changes, voting results, or other report types. It fits best under Regulatory Filings (RNS) as a general regulatory announcement that does not fit other specific categories.
2024-06-18 Chinese

Browse filings by year

28 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.